World-first clinical trial launched in Southampton for a fridge-free vaccine
The Stablepharma tetanus-diphtheria vaccine (SPVX02) is completely stable at room temperature and the firm behind it says up to 60 other vaccines may benefit from the advanced technology.
The first-in-human trial of the vaccine is taking place at the National Institute for Health and Care Research (NIHR) Southampton clinical research facility at University Hospital Southampton.
One of the biggest barriers to people getting vaccines in some parts of the world is the 'cold chain' required to keep vaccines cold from manufacture to the point they are injected.
The World Health Organisation (WHO) estimates that up to half of vaccines are wasted globally every year – largely because of a lack of temperature control and the logistics needed to support an unbroken cold-chain.
UK-based biotech company Stablepharma has shown it can convert existing approved vaccines to fridge-free versions that can be stored for long periods of time at room temperature.
Health and Social Care Secretary, Wes Streeting, said: 'For years, vaccines have been held back by the need to be stored in a fridge – causing endless amounts of wastage and making it difficult to deliver them to remote communities.
'But thanks to this Government's vision and our investment through the National Institute for Health and Care Research, all that could be about to change.
'We are leading the charge by pushing through the world's first trial for fridge-free vaccines.
'This could be a real game changer and lifesaver globally – as it unlocks new ways for poorer nations to deliver vaccines to their patients, where they're often needed the most.
'Groundbreaking science is amongst the things that Britain does best, and this innovation reaffirms our position as a world leader in vaccine development and research, boosting growth and economic security – the cornerstone of our Plan for Change.'
The clinical trial is being led by Professor Saul Faust from the University of Southampton and Stablepharma chief development officer, Dr Karen O'Hanlon.
Prof Faust said: 'It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the south coast to take part.
'This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold-chain.'
The trial is expected to complete this summer, with results published by the end of the year.
Stablepharma hopes the new vaccine will be in use globally by 2027.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
5 minutes ago
- BBC News
German pharma firm signs deal worth up to $1bn with QUB spin out
A medical technology company founded by Queen's University academics has signed a licensing agreement with a major pharmaceutical firm which could ultimately be worth up to $1bn (£744.1m).Re-Vana Therapeutics, which was set up in 2016, develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of care for major benefit of its technology is that it reduces the number of eye injections patients require making them more likely to follow their Ingelheim, a German pharmaceutical firm, is licensing the drug delivery system to combine it with its eye medications. The German firm will take responsibility for regulatory approvals and global commercialization of products developed using the Re-Vana Ingelheim said the deal involves "upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1bn for the initial three targets, in addition to royalty payments on net sales".Re-Vana was founded by Professor Raj Thakur and Professor David Jones with investors including Qubis, the commercialisation arm of Queen's company is now based in the US but still has its research base in O'Rourke, Re-Vana's Chief Executive Officer, said the collaboration with Boehringer Ingelheim is a "transformational moment".The deal has also been welcomed by NI Secretary of State Hillary Benn who said it "represents a huge vote of confidence in Northern Ireland's innovation and skills".
Reuters
8 minutes ago
- Reuters
Revvity trims 2025 profit forecast on soft demand for diagnostics in China
July 28 (Reuters) - Medical equipment maker Revvity (RVTY.N), opens new tab on Monday lowered its full-year adjusted profit forecast as it expects demand for its diagnostics products in some international markets to remain soft, sending the company's shares down 8% premarket. The company, which makes more than 50% of its annual revenues from markets outside the United States, said sales of its diagnostics products in China, a key market, declined by double digits during the second quarter. Revvity said last quarter that it expected to take a $135 million hit from potential tariffs on China. It planned to adjust its manufacturing footprint and was in discussions with alternative suppliers, to mitigate impact from tariffs. The Massachusetts-based company now expects adjusted profit for 2025 between $4.85 and $4.95 per share, compared with its previous forecast of $4.90 to $5.00 per share. Analysts were expecting a profit of $4.93 per share, according to data compiled by LSEG. Revvity expects revenue of $2.84 billion to $2.88 billion for the full year, helped in part by a weaker U.S. dollar. It had previously forecast annual revenue of $2.83 billion to $2.87 billion and analysts were expecting $2.85 billion. The forecast cut from Revvity is in contrast to results from its peers Thermo Fisher Scientific (TMO.N), opens new tab and Danaher (DHR.N), opens new tab, which raised their annual profit forecasts last week. Second-quarter results, however, came in line with industry peers, as Revvity posted strong quarterly profit and sales of its life sciences products were $365.9 million, above estimates of $353.9 million. Thermo Fisher, Danaher and others have flagged robust demand across regions for their drug development products such as instruments and analytical tools used in trials and manufacturing, after two years of weak biotech funding.
The Guardian
13 minutes ago
- The Guardian
Edinburgh University's ‘skull room' highlights its complicated history with racist science
Hundreds of skulls are neatly and closely placed, cheekbone to cheekbone, in tall, mahogany-framed glass cabinets. Most carry faded, peeling labels, some bear painted catalogue numbers; one has gold teeth; and the occasional one still carries its skin tissue. This is the University of Edinburgh's 'skull room'. Many were voluntarily donated to the university; others came from executed Scottish murderers; some Indigenous people's skulls were brought to Scotland by military officers on expeditions or conquest missions. Several hundred were collected by supporters of the racist science of phrenology – the discredited belief that skull shape denoted intelligence and character. Among them are the skulls of two brothers who died while studying at Edinburgh. Their names are not recorded in the skull room catalogue, but cross-referencing of matriculation and death records suggests they were George Richards, a 21-year-old medic who died of smallpox in 1832, and his younger brother, Robert Bruce, 18, a divinity scholar who died of typhoid fever in 1833. Exactly how the Richards brothers' skulls came to be separated from their bodies, recorded as interred in the South Leith parish church cemetery, is unknown. But they were almost certainly acquired by the Edinburgh Phrenological Society to study supposed racial difference. Researchers believe their case exemplifies the challenging questions facing the university, which, it has now emerged, played a pivotal role in the creation and perpetuation of racist ideas about white superiority and racial difference from the late 1700s onwards – ideas taught to thousands of Edinburgh students who dispersed across the British empire. University records studied by Dr Simon Buck suggest the brothers were of mixed African and European descent, born in Barbados to George Richards, an Edinburgh-educated doctor who practised medicine on sugar plantations and who owned enslaved people – possibly including George and Robert Bruce's mother. Edinburgh Phrenological Society's 1858 catalogue records the skulls (listed as No 1 and No 2) as having belonged to 'mulatto' students of divinity and medicine. 'It can be assumed that the racialisation of these two individuals as 'mulatto' – a hybrid racial category that both fascinated and bewildered phrenologists – is what aroused interest among members of the society in the skulls of these two students,' Edinburgh's decolonisation report concludes. The brothers' skulls are among the roughly 400 amassed by the society and later absorbed into the anatomical museum's collection, which now contains about 1,500 skulls. These are held in the Skull Room, to which The Guardian was granted rare access. Many of these ancestral remains, the report states, 'were taken, without consent, from prisons, asylums, hospitals, archaeological sites and battlefields', with others 'having been stolen and exported from the British empire's colonies', often gifted by a global network of Edinburgh alumni. 'We can't escape the fact that some of [the skulls] will have been collected with the absolute express purpose of saying, 'This is a person from a specific race, and aren't they inferior to the white man',' said Prof Tom Gillingwater, the chair of anatomy at the University of Edinburgh, who now oversees the anatomical collection. 'We can't get away from that.' The Edinburgh Phrenological Society was founded by George Combe, a lawyer, and his younger brother, Andrew, a doctor, with roughly a third of its early members being physicians. Both were students at the university, and some Edinburgh professors were active members. Through its acquisition of skulls from across the globe, the society played a central role in turning the 'science' of phrenology, which claimed to decode an individual's intellect and moral character from bumps and grooves on the skull, into a tool of racial categorisation that placed the white European man at the top of a supposed hierarchy. George Combe's book, The Constitution of Man, was a 19th-century international bestseller and the Combe Trust (founded with money made from books and lecture tours promoting phrenology) endowed Edinburgh's first professorship in psychology in 1906 and continues to fund annual Combe Trust fellowships in the Institute for Advanced Studies in the Humanities. Phrenology was criticised by some of Edinburgh's medical elite for its unscientific approach. But some of its most vocal critics were nonetheless persuaded that immutable biological differences in intelligence and temperament existed between populations, a study by Dr Ian Stewart for the university's decolonisation report reveals. These included Alexander Monro III, an anatomy professor at the University of Edinburgh medical school, who lectured 'that the Negro skull, and consequently the brain, is smaller than that of the European', and Robert Jameson, a regius professor of natural history, whose lectures at the university in the 1810s included a hierarchical racial diagram of brain size and intelligence. Despite the fact that phrenology was never formally taught at Edinburgh, and its accuracy was heavily contested by Edinburgh academics, the skull room, which is closed to the public, was built partly to house its collection by the then professor of anatomy Sir William Turner, when he helped oversee the construction of its new medical school in the 1880s. Among its reparatory justice recommendations of Edinburgh's investigation is that the university provide more support for the repatriation of ancestral remains to their original communities. This, Gillingwater suggested, possibly underplays the complexities involved – even for cases such as the Richards brothers. He regards the circumstantial evidence in their case as 'strong' but says it does not meet the forensic threshold required for conclusive identification. 'From a legal perspective, it wouldn't be watertight,' said Gillingwater. 'I would never dream of returning remains to a family when I didn't know who they definitely were.' Active engagement surrounding repatriation is taking place in relation to several of the skulls from the phrenology collection; more than 100 have already been repatriated to their places of origin. But each case takes time building trust with communities and in some cases navigating geopolitical tensions over which descendent community has the strongest claim to the remains. 'To look at perhaps repatriation, burials, or whatever, it's literally years of work almost for each individual case,' said Gillingwater. 'And what I found is that every individual culture you deal with wants things done completely differently.' Many of the skulls will never be identified and their provenance is likely to remain unknown. 'That is something that keeps me awake at night,' said Gillingwater. 'For some of our skulls, I know that whatever we do, we're never going to end up with an answer.' 'All I can offer at the minute is that we just continue to care for them,' he added. 'They've been with us, many of them, for a couple of hundred years. So we can look after them. We can care for them. We can treat them with that dignity and respect they all deserve individually.'
